AVCO

Avalon GloboCare Corp. [AVCO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AVCO Stock Summary

In the News

09:44 30 Nov 2023 AVCO

Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition

Avalon GloboCare Corp (NASDAQ:ALBT) has encouraged its shareholders to vote on a number of key proposals at its upcoming annual meeting to be held on December 29, 2022, at 11am Eastern Time. Shareholders can vote on a new proposed board composition to reflect the company's continued US focus and acquisition of Laboratory Services MSO LLC, Avalon said in a statement.

10:24 30 Nov 2023 AVCO

Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M

Avalon GloboCare Corp (NASDAQ:AVCO) is set to buy a 60% stake in Laboratory Services MSO as it expands its focus on lab testing and services in what it called a 'transformative' deal worth $31 million. California-headquartered Laboratory Services has completed over 600,000 tests since inception.

09:15 30 Nov 2023 AVCO

Stock Market Today: What Happened & 3 Penny Stocks To Watch Now

What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:28 30 Nov 2023 AVCO

Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform

Avalon GloboCare Corp (NASDAQ:AVCO) has received a notice of allowance from the US Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The company's QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said.

10:46 30 Nov 2023 AVCO

Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews

Avalon GloboCare Corp (NASDAQ:AVCO) said that an article featuring its QTY protein code technology was published in Chemical Reviews, the official journal of the American Chemical Society.  The publication, titled “Protein Design: From the Aspect of Water Solubility and Stability,” discusses the innovative QTY protein design code, which Avalon co-designed, as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications.

09:59 30 Nov 2023 AVCO

Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer

Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could accelerate development of therapeutic monoclonal antibodies to treat cancer. Developed by Avalon, the QTY code technology is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins for use in clinical applications, including drug development.

09:00 30 Nov 2023 AVCO

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City.

10:53 30 Nov 2023 AVCO

Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments

Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies, the company announced. LDHI is a hematology research institute based in Beijing developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms.

10:29 30 Nov 2023 AVCO

Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials

Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The company said the patents were filed with US Patent and Trademark Office, the China National Trademark Office, and under the Patent Cooperation Treaty covering 36 countries.

11:57 30 Nov 2023 AVCO

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.

AVCO Financial details

Company Rating
Neutral
Market Cap
5.26M
Income
-12.4M
Revenue
1.23M
Book val./share
1.56
Cash/share
0.03
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
28 Mar 2023
P/E
-0.33
Forward P/E
-
PEG
-0.22
P/S
6.31
P/B
0.26
P/C
17.53
P/FCF
-0.68
Quick Ratio
0.2
Current Ratio
0.27
Debt / Equity
0.48
LT Debt / Equity
0.38
-
-
EPS (TTM)
-1.25
EPS next Y
-
EPS next Q
-
EPS this Y
24.77%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.72%
Revenue last 5Y
-5.11%
Revenue Q/Q
7.95%
EPS Q/Q
-44%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-50%
ROE
-174%
ROC
-0.63%
Gross Margin
21%
Oper. Margin
-1785%
Profit Margin
-1724%
Payout
-
Shs Outstand
10M
Shs Float
3.22M
-
-
-
-
Target Price
-
52W Range
0.3731-1.07
52W High
-
52W Low
-
RSI
52
Rel Volume
2.28
Avg Volume
189.95K
Volume
432.17K
Perf Week
48.43%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.806311
-
-
Volatility
0.07%, 0.06%
Prev Close
21.88%
Price
0.5259
Change
31.21%

AVCO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.220.210.170.160.13
Net income per share
-1.08-2.41-1.61-1.09-1.36
Operating cash flow per share
-0.61-0.94-0.95-0.59-0.75
Free cash flow per share
-0.63-0.99-0.95-0.59-0.75
Cash per share
0.310.10.090.10.21
Book value per share
1.680.590.520.361.2
Tangible book value per share
1.390.590.520.361.2
Share holders equity per share
1.680.590.520.361.2
Interest debt per share
0.330.440.490.410.87
Market cap
198.01M144.98M89.05M69.63M48.51M
Enterprise value
196.76M147.4M92.06M72.12M51.09M
P/E ratio
-25.47-8.01-6.96-7.54-3.83
Price to sales ratio
126.7493.7664.6350.0640.35
POCF ratio
-45.04-20.48-11.8-13.86-6.89
PFCF ratio
-43.91-19.44-11.8-13.81-6.89
P/B Ratio
16.3432.4721.6322.574.35
PTB ratio
16.3432.4721.6322.574.35
EV to sales
125.9495.3266.8251.8542.5
Enterprise value over EBITDA
-27.68-7.99-7.59-8.53-7.16
EV to operating cash flow
-44.76-20.82-12.2-14.35-7.26
EV to free cash flow
-43.64-19.77-12.2-14.3-7.26
Earnings yield
-0.04-0.12-0.14-0.13-0.26
Free cash flow yield
-0.02-0.05-0.08-0.07-0.15
Debt to equity
0.170.710.911.070.41
Debt to assets
0.150.30.360.320.23
Net debt to EBITDA
0.18-0.13-0.25-0.29-0.36
Current ratio
3.180.550.50.30.66
Interest coverage
-24.25-221.54-73.8-44.06-2.08
Income quality
0.550.390.60.550.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
4.9210.958.685.914.71
Research and developement to revenue
01.150.640.740.61
Intangibles to total assets
0.090000
Capex to operating cash flow
0.030.05000
Capex to revenue
-0.07-0.240-0.010
Capex to depreciation
-0.22-0.740-0.040
Stock based compensation to revenue
1.985.963.991.520.92
Graham number
6.395.684.332.986.05
ROIC
-0.52-2.4-1.57-1.37-0.5
Return on tangible assets
-0.64-1.73-1.23-0.9-0.64
Graham Net
0.02-0.64-0.66-0.72-0.7
Working capital
2.48M-1.26M-1.31M-3.08M-1.21M
Tangible asset value
10M4.47M4.12M3.08M11.16M
Net current asset value
1.48M-4.45M-4.96M-5.83M-6.22M
Invested capital
0.170.710.911.070.41
Average receivables
50.44K148.06K139.64K51.31K100.92K
Average payables
3.36K45.51K42.16K00
Average inventory
7.83K258.58K498.71K461.62K214.99K
Days sales outstanding
12.257.579.3817.6440.87
Days payables outstanding
2.0825.51000
Days of inventory on hand
4.04152.54182.31160.720
Receivables turnover
29.926.3438.9320.698.93
Payables turnover
175.414.31000
Inventory turnover
90.372.3922.270
ROE
-0.64-4.05-3.11-2.99-1.14
Capex per share
-0.02-0.05000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.030.030.030.030.03
Net income per share
-0.95-0.28-0.58-0.25-0.14
Operating cash flow per share
-0.25-0.21-0.18-0.25-0.12
Free cash flow per share
-0.25-0.21-0.19-0.25-0.12
Cash per share
0.410.210.090.060.03
Book value per share
0.471.21.991.771.56
Tangible book value per share
0.471.21.991.771.56
Share holders equity per share
0.471.21.991.771.56
Interest debt per share
0.810.510.570.770.79
Market cap
62.2M48.51M19.83M15.78M8.66M
Enterprise value
62.86M51.09M24.5M22.72M16.42M
P/E ratio
-1.68-4.66-0.86-1.55-1.46
Price to sales ratio
195.97163.766.9651.4226.15
POCF ratio
-26.07-24.7-10.81-6.25-6.42
PFCF ratio
-26.07-24.7-10.69-6.25-6.42
P/B Ratio
13.594.3510.870.51
PTB ratio
13.594.3510.870.51
EV to sales
198.06172.4282.7374.0449.58
Enterprise value over EBITDA
-34.42-23.6-9.68-12.73-15.47
EV to operating cash flow
-26.34-26.01-13.35-9-12.18
EV to free cash flow
-26.34-26.01-13.21-8.99-12.18
Earnings yield
-0.15-0.05-0.29-0.16-0.17
Free cash flow yield
-0.04-0.04-0.09-0.16-0.16
Debt to equity
1.010.410.280.420.48
Debt to assets
0.360.230.180.250.27
Net debt to EBITDA
-0.36-1.19-1.84-3.89-7.31
Current ratio
1.340.660.270.240.13
Interest coverage
-0.48-16.02-17.05-7.57-2.6
Income quality
0.440.810.660.990.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
4.225.36.515.583.32
Research and developement to revenue
0.540.640.310.060
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
00-0.07-0.010
Capex to depreciation
00-0.21-0.020
Stock based compensation to revenue
0.510.421.11.760.57
Graham number
3.182.745.083.142.2
ROIC
-0.29-0.15-0.21-0.09-0.07
Return on tangible assets
-0.72-0.13-0.19-0.08-0.05
Graham Net
-0.44-0.7-0.99-1.11-1.16
Working capital
1.12M-1.21M-3.79M-4.54M-5.83M
Tangible asset value
4.58M11.16M19.91M18.15M16.82M
Net current asset value
-3.88M-6.22M-9.67M-11M-12.28M
Invested capital
1.010.410.280.420.48
Average receivables
112.76K128.43K134.19K134.9K126.36K
Average payables
228.49K40.29K000
Average inventory
236.65K69.59K165.09K456.84K452.8K
Days sales outstanding
34.6640.8940.6439.931.69
Days payables outstanding
29.340000
Days of inventory on hand
50.680119.61213.99100.63
Receivables turnover
2.62.22.212.262.84
Payables turnover
3.070000
Inventory turnover
1.7800.750.420.89
ROE
-2.02-0.23-0.29-0.14-0.09
Capex per share
00000

AVCO Frequently Asked Questions

What is Avalon GloboCare Corp. stock symbol ?

Avalon GloboCare Corp. is a US stock , located in Freehold of New jersey and trading under the symbol AVCO

What is Avalon GloboCare Corp. stock quote today ?

Avalon GloboCare Corp. stock price is $0.5259 today.

Is Avalon GloboCare Corp. stock public?

Yes, Avalon GloboCare Corp. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap